Effect of topical recombinant TGF-β on healing of partial thickness injuries

Jones, Shawn C. T.; Curtsinger, Luke J.; Whalen, James; Pietsch, James D.; Ackerman, Douglas; Brown, Gregory L.; Schultz, Gregory S.

doi:10.1016/0022-4804(91)90119-7

Cited by 38 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports have shown that IL-10 suppresses wound healing, whereas TGF-b and TNF-a are necessary for wound healing [17][18][19]. IL-10 inhibits the synthesis of a number of cytokines including IFN-g, IL-2, TNF-a, and granulocyte macrophage colony-stimulating factor (GM-CSF) produced by activated macrophages and T lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing

Hasegawa¹,

Higashi²,

Matsushita³

et al. 2013

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing

Hasegawa¹,

Higashi²,

Matsushita³

et al. 2013

Journal of Dermatological Science

View full text Add to dashboard Cite

“…There have been several studies indicating an increase in collagen production during the repair process by applying exogenous TGF‐β (Mustoe et al, 1987; Beck et al, 1990; Jones et al, 1991; Quaglino et al, 1991; Terrell et al, 1993). However, no experimental findings are available regarding activation of the collagen gene promoter in wound healing.…”

Section: Discussionmentioning

confidence: 99%

“…It is secreted from macrophages and lymphocytes (Kehrl et al, 1986; Assoian et al, 1987) and increases the production of collagen and fibronectin by fibroblasts in vitro (Raghow et al, 1987; Varga et al, 1987). Exogenous addition of TGF‐β has been reported to stimulate wound healing (Mustoe et al, 1987; Beck et al, 1990; Jones et al, 1991; Quaglino et al, 1991; Terrell et al, 1993). TGF‐β is also known to have indirect mitogenic activity on fibroblasts.…”

Section: Discussionmentioning

confidence: 99%

Severe intravascular hemolysis after transcatheter closure of a large patent ductus arteriosus using the Amplatzer duct occluder: Successful resolution by intradevice coil deployment

Joseph¹,

Mandalay²,

Zacharias³

et al. 2002

Cathet Cardio Intervent

View full text Add to dashboard Cite

A 21-year-old female developed severe unremitting intravascular hemolysis following closure of a large patent ductus arteriosus using an Amplatzer duct occluder. Percutaneous deployment of fibered platinum coils within the nitinol wire cage of the Amplatzer duct occluder abolished the residual shunt through the device and resulted in cessation of intravascular hemolysis and reversal of its adverse sequelae.

show abstract

“…The dosing regimen of TGF-ßl used to induce scar formation in day 14 fetal mouse limbs in the present study was chosen on the basis of clinical studies that showed fibrosis after daily administration ofa similar dose of TGF-ßl applied topically to adult wounds . 24,26 This dose is admittedly pharmacologic . In preliminary studies, it was determined that TGF-ßl was only effective when prepared in polypropylene vials immediately before application and applied directly to the wounded limb .…”

Section: Discussionmentioning

confidence: 99%

The role of transforming growth factor‐β in the conversion from “scarless” healing to healing with scar formation

Houghton

Keefer

Krummel

1995

Wound Repair Regeneration

View full text Add to dashboard Cite

The objective of this study was to elucidate mediators responsible for conversion of "scarless" wound healing seen in wounded, day 14 fetal mouse limbs to healing with scar formation seen in wounded, day 18 fetal mouse limbs. Wounded, day 14 limbs were grown in a serum-free organ culture system in which either phosphate-buffered saline solution or human recombinant transforming growth factor beta-1 (1 microg/ml) was added daily. Wounded, day 18 limbs were also maintained in the same organ culture system with either phosphate-buffered saline solution or neutralizing antibody to transforming growth factor-beta (1 microg/ml) treatment. Limb cross sections were examined qualitatively with Masson's Trichrome stain and quantitatively by spectrophotometric analysis of Sirius Red and Fast Green dyes which bind to collagen and noncollagenous protein, respectively. Both qualitative and quantitative analyses showed the following: there was greater collagen deposition in day 18 versus day 14 limbs by 7 days after wounding, scar formation in day 18 limbs was attenuated by the addition of anti-transforming growth factor-beta, and there was the addition of transforming growth factor-beta-augmented collagenous scar formation in wounded regions of day 14 limbs. These results strongly suggest that transforming growth factor-beta present in the local wound environment is, at least in part, responsible for the conversion of "scarless" healing occurring in wounded, day 14 limbs to scar formation present in wounded, day 18 limbs.

show abstract

Effect of topical recombinant TGF-β on healing of partial thickness injuries

Cited by 38 publications

References 27 publications

Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing

Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing

Severe intravascular hemolysis after transcatheter closure of a large patent ductus arteriosus using the Amplatzer duct occluder: Successful resolution by intradevice coil deployment

The role of transforming growth factor‐β in the conversion from “scarless” healing to healing with scar formation

Contact Info

Product

Resources

About